Key facts
- GluBio Pharmaceutical’s last known valuation is $311.0M (Jun 2022).
- It has raised $122.0M; the latest was Later Stage VC ($30.0M) in Feb 2026.
- Notable investors include Qiming Venture Partners, GL Ventures, Legend Capital, K2VC, E Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for GluBio Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for GluBio Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GluBio Pharmaceutical
Developer of molecular glue degraders designed for pharmaceutical companies and clinical research organizations. The company offers research and development of innovative molecular glue degraders, thereby enabling clients to advance novel therapeutic modalities that address critical unmet medical needs in patient care.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- glubiotx.com/
- Ownership
- Privately Held (backing)
GluBio Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GluBio Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GluBio Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.